Implementing treatment strategies for different types of depression

Journal of Clinical Psychiatry

Volumn 77, Issue , 2016, Pages 9-15

  McIntyre, Roger S ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; C REACTIVE PROTEIN; ESCITALOPRAM; LITHIUM SALT; MIRTAZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; PSYCHOSTIMULANT AGENT; QUETIAPINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; THYROID HORMONE; VENLAFAXINE;

ADD ON THERAPY; ANXIETY DISORDER; ARTICLE; BODY MASS; BODY WEIGHT DISORDER; CENTER FOR EPIDEMIOLOGICAL STUDIES DEPRESSION SCALE; DIAGNOSTIC ACCURACY; DSM-5; ELECTROCONVULSIVE THERAPY; EXTRAPYRAMIDAL SYMPTOM; HEREDITY; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MAJOR DEPRESSION; MONOTHERAPY; OBESITY; PATIENT HEALTH QUESTIONNAIRE 2; PATIENT HEALTH QUESTIONNAIRE 9; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOTHERAPY; SEDATION; TREATMENT OUTCOME; WEIGHT GAIN; ZUNG SELF RATING DEPRESSION SCALE; COMBINATION DRUG THERAPY; DEPRESSIVE DISORDER, MAJOR; MULTIMODALITY CANCER THERAPY; PROCEDURES; REMISSION; RISK FACTOR;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER, MAJOR; DRUG THERAPY, COMBINATION; HUMANS; PSYCHOTHERAPY; REMISSION INDUCTION; RISK FACTORS;

EID: 84959560805     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.14077su1c.02     Document Type: Article

References (38)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition. Arlington, VA: American Psychiatric Association; 2013.
2. Greenberg PE, Fournier AA, Sisitsky T, et al. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry. 2015;76(2): 155-162. doi: 10.408/JCP.14m09298 PubMed
3. Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: Review and meta-Analysis. Am J Psychiatry. 2000;157(10): 1552-1562. doi: 10.176/api.ajp.157.10.152 PubMed
4. Fava M, Kendler KS. Major depressive disorder. Neuron. 2000;28(2): 335-341. doi: 10.1016/S0896-6273(0)012-4 PubMed
5. Goodkind M, Eickhoff SB, Oathes DJ, et al. Identification of a common neurobiological substrate for mental illness. JAMA Psychiatry. 2015;72(4): 305-315. doi: 10.101/jamapsychiatry.2014.206 PubMed
6. Katon WJ. Epidemiology and treatment of depression in patients with chronic medical illness. Dialogues Clin Neurosci. 2011;13(1): 7-23. PubMed
7. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-Term outcomes in depressed outpatients requiring one or several treatment steps: A STAR ∗D report. Am J Psychiatry. 2006;163(11): 1905-1917. doi: 10.176/api.ajp.163.1.1905 PubMed
8. McIntyre RS. Using measurement strategies to identify and monitor residual symptoms. J Clin Psychiatry. 2013;74(suppl 2): 14-18. doi: 10.408/JCP.12084su1c.03 PubMed
9. Zimmerman M, McGlinchey JB, Posternak MA, et al. How should remission from depression be defined? the depressed patient's perspective. Am J Psychiatry. 2006;163(1): 148-150. doi: 10.176/api.ajp.163.1.148 PubMed
10. Kemp AH, Gordon E, Rush AJ, et al. Improving the prediction of treatment response in depression: Integration of clinical, cognitive, psychophysiological, neuroimaging, and genetic measures. CNS Spectr. 2008;13(12): 1066-1086, quiz 1087-1088. PubMed
11. Gelenberg AJ. Using assessment tools to screen for, diagnose, and treat major depressive disorder in clinical practice. J Clin Psychiatry. 2010;71 (suppl e1): E01. doi: 10.408/JCP.9058se1c.01gry PubMed
12. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: Validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9): 606-613. doi: 10.1046/j.1525-1497.201.01609606.x PubMed
13. Szegedi A, Jansen WT, van Willigenburg APP, et al. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: A meta-Analysis including 6562 patients. J Clin Psychiatry. 2009;70(3): 344-353. doi: 10.408/JCP.07m03780 PubMed
14. Uher R, Tansey K, Henigsberg N, et al; STAR ∗D Investigators. Common genetic variation and antidepressant efficacy in major depressive disorder: A meta-Analysis of three genome-wide pharmacogenetic studies. Am J Psychiatry. 2013;170(2): 207-217. doi: 10.176/api.ajp.2012.12020237 PubMed
15. Gelenberg AJ, Freeman MP, Markowitz JC, et al. Practice Guideline for the Treatment of Patients With Major Depressive Disorder. Arlington, VA: American Psychiatric Association; 2010.
16. Lopresti AL, Maker GL, Hood SD, et al. A review of peripheral biomarkers in major depression: The potential of inflammatory and oxidative stress biomarkers. Prog Neuropsychopharmacol Biol Psychiatry. 2014;48: 102-111. doi: 10.1016/j.pnpbp.2013.09.017 PubMed
17. Uher R, Tansey KE, Dew T, et al. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. Am J Psychiatry. 2014;171(12): 1278-1286. doi: 10.176/api.ajp.2014.1401094 PubMed
18. Liu CS, Carvalho AF, McIntyre RS. Towards a "metabolic" subtype of major depressive disorder: Shared pathophysiological mechanisms may contribute to cognitive dysfunction. CNS Neurol Disord Drug Targets. 2014;13(10): 1693-1707. doi: 10.2174/1871527313614130204031 PubMed
19. Lin CH, Chen CC, Wong J, et al. Both body weight and BMI predicts improvement in symptom and functioning for patients with major depressive disorder. J Affect Disord. 2014;161: 123-126. doi: 10.1016/j.jad.2014.02.039 PubMed
20. Uher R, Mors O, Hauser J, et al. Body weight as a predictor of antidepressant efficacy in the GENDEP project. J Affect Disord. 2009;118(1-3): 147-154. doi: 10.1016/j.jad.209.02.013 PubMed
21. Fava M, Rush AJ, Alpert JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: A STAR ∗D report. Am J Psychiatry. 2008;165(3): 342-351. doi: 10.176/api.ajp.207.061868 PubMed
22. Lam RW, Kennedy SH, Grigoriadis S, et al; Canadian Network for Mood and Anxiety Treatments (CANMAT). Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults, III: Pharmacotherapy. J Affect Disord. 2009;117(suppl 1): S26-S43. doi: 10.1016/j.jad.209.06.041 PubMed
23. Arnow BA, Blasey C, Williams LM, et al. Depression subtypes in predicting antidepressant response: A report from the iSPOT-D trial. Am J Psychiatry. 2015;172(8): 743-750. doi: 10.176/api.ajp.2015.14020181 PubMed
24. Connolly KR, Thase ME. If at first you don't succeed: A review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs. 2011;71(1): 43-64. doi: 10.2165/1587620-0-0 PubMed
25. Papakostas GI, Thase ME, Fava M, et al. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? a meta-Analysis of studies of newer agents. Biol Psychiatry. 2007;62(11): 1217-1227. doi: 10.1016/j.biopsych.207.03.027 PubMed
26. Warden D, Trivedi MH, Carmody T, et al. Adherence to antidepressant combinations and monotherapy for major depressive disorder: A CO-MED report of measurement-based care. J Psychiatr Pract. 2014;20(2): 118-132. doi: 10.1097/01.pra.045246.46424.fe PubMed
27. Grant RW, Devita NG, Singer DE, et al. Polypharmacy and medication adherence in patients with type 2 diabetes. Diabetes Care. 2003;26(5): 1408-1412. doi: 10.237/diacare.26.5.1408 PubMed
28. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: A meta-Analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009;166(9): 980-991. doi: 10.176/api.ajp.209.09030312 PubMed
29. Chang CM, Sato S, Han C. Evidence for the benefits of nonantipsychotic pharmacological augmentation in the treatment of depression. CNS Drugs. 2013;27(suppl 1): S21-S27. doi: 10.107/s40263-012-030-1 PubMed
30. Madhoo M, Keefe RS, Roth RM, et al. Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder. Neuropsychopharmacology. 2014;39(6): 1388-1398. doi: 10.1038/np.2013.34 PubMed
31. Feetam C. Are two antidepressants always better than one? Prog Neurol Psychiatry. 2012;16(3): 5-8. doi: 10.102/pnp.234
32. Rush AJ, Trivedi MH, Stewart JW, et al. Combining medications to enhance depression outcomes (CO-MED): Acute and long-Term outcomes of a single-blind randomized study. Am J Psychiatry. 2011;168(7): 689-701. doi: 10.176/api.ajp.201.101645 PubMed
33. Iadarola ND, Niciu MJ, Richards EM, et al. Ketamine and other N-methyl-Daspartate receptor antagonists in the treatment of depression: A perspective review. Ther Adv Chronic Dis. 2015;6(3): 97-114. doi: 10.17/20406231579059 PubMed
34. Price RB, Iosifescu DV, Murrough JW, et al. Effects of ketamine on explicit and implicit suicidal cognition: A randomized controlled trial in treatment-resistant depression. Depress Anxiety. 2014;31(4): 335-343. doi: 10.102/da.253 PubMed
35. Köhler O, Benros ME, Nordentoft M, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: A systematic review and meta-Analysis of randomized clinical trials. JAMA Psychiatry. 2014;71(12): 1381-1391. doi: 10.101/jamapsychiatry.2014.161 PubMed
36. Maes M, Nowak G, Caso JR, et al. Toward omics-based, systems biomedicine, and path and drug discovery methodologies for depression-inflammation research [published online ahead of print May 2, 2015]. Mol Neurobiol. doi: 10.107/s12035-015-9183-5 PubMed
37. Cuijpers P, Andersson G, Donker T, et al. Psychological treatment of depression: Results of a series of meta-Analyses. Nord J Psychiatry. 2011;65(6): 354-364. doi: 10.3109/0803948.201.596570 PubMed
38. Parikh SV, Segal ZV, Grigoriadis S, et al; Canadian Network for Mood and Anxiety Treatments (CANMAT). Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication. J Affect Disord. 2009;117(suppl 1): S15-S25.